Drug Type Small molecule drug |
Synonyms- |
Action antagonists |
Mechanism A1R antagonists(Adenosine A1 receptor antagonists), A2aR antagonists(Adenosine A2a receptor antagonists), β-adrenoceptors antagonists(Beta adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC8H10N4O2 |
InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N |
CAS Registry58-08-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute migraine | Phase 2 | United States | 01 Jan 2007 |
Phase 2 | 60 | placebo (Placebo) | jmuzpoyael(dqxelymeqo) = oqqqaaqbou wwmbpjyazm (ipcwywnyuo, jhlhmcidov - wdqhxtwwnt) View more | - | 24 Feb 2017 | ||
(Low Dose) | jmuzpoyael(dqxelymeqo) = uiqfrqhvqz wwmbpjyazm (ipcwywnyuo, umlmwzsgrh - cqkvxkoaid) View more |